Fable Therapeutics, Inc.

Fable Therapeutics is an innovative biotechnology company focused on designing and developing protein-based therapeutics through advanced machine learning techniques, aiming to transform drug discovery and address various therapeutic needs. Founded in 2022, Fable Therapeutics, Inc. is based in San Francisco, US. The company specializes in creating programmable biomedicines using a unique machine learning platform.

Fable has secured USD 10. 00 mn in Seed funding from investors including Data Collective and Versant Ventures, with a total amount raised of USD 10. 00 mn. The latest funding round occurred on October 24, 2024.

There are no mentions of pivots or subsidiaries, and further details on the founder are not provided. Fable Therapeutics specializes in the design and development of novel protein-based therapeutics by integrating advanced machine learning techniques with protein engineering. Their core offerings revolve around a unique machine learning platform that enables the creation of programmable biomedicines, addressing a range of therapeutic needs. The company focuses on understanding the intricate relationships between linear amino acid sequences and their corresponding protein structures and functions, targeting various therapeutic areas.

Fable serves a diverse client base, including pharmaceutical companies and research institutions across North America, Europe, and Asia, helping them expedite the development of effective treatments. Fable Therapeutics generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research institutions. The company engages in tailored agreements for access to their proprietary machine learning platform and the resulting protein-based therapeutics, structured around project-based collaborations. Clients benefit from Fable’s advanced capabilities in protein design, aligning their objectives with innovative drug discovery processes.

Fable Therapeutics plans to leverage its recent Seed funding of USD 10. 00 mn raised on October 24, 2024, to enhance its machine learning platform and develop new therapeutic products. The company aims to expand its reach into additional international markets, including specific targets in Europe and Asia, by 2025, seeking to establish partnerships that promote the use of their programmable biomedicines.